Citation: Shihori Tanabe, Kazuhiko Aoyagi, Hiroshi Yokozaki, Hiroki Sasaki. Molecular pathway network of EFNA1 in cancer and mesenchymal stem cells[J]. AIMS Cell and Tissue Engineering, 2018, 2(2): 58-77. doi: 10.3934/celltissue.2018.2.58
[1] | Barquilla A, Pasquale EB (2015) Eph receptors and ephrins: therapeutic opportunities. Annu Rev Pharmacol Toxicol 55: 465–487. doi: 10.1146/annurev-pharmtox-011112-140226 |
[2] | Pasquale EB (2008) Eph-ephrin bidirectional signaling in physiology and disease. Cell 133: 38–52. doi: 10.1016/j.cell.2008.03.011 |
[3] | Lindberg RA, Hunter T (1990) cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the ephelk family of protein kinases. Mol Cell Biol 10: 6316–6324. doi: 10.1128/MCB.10.12.6316 |
[4] | Beauchamp A, Debinski W (2012) Ephs and ephrins in cancer: Ephrin-A1 signaling. Semin Cell Dev Biol 23: 109–115. doi: 10.1016/j.semcdb.2011.10.019 |
[5] | Dunne PD, Dasgupta S, Blayney JK, et al. (2016) EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer. Clin Cancer Res 22: 230–242. doi: 10.1158/1078-0432.CCR-15-0603 |
[6] | Pasquale EB (2010) Eph receptors and ephrins in cancer: bidirectional signaling and beyond. Nat Rev Cancer 10: 165–180. doi: 10.1038/nrc2806 |
[7] | Gale NW, Holland SJ, Valenzuela DM, et al. (1996) Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 17: 9–19. doi: 10.1016/S0896-6273(00)80276-7 |
[8] | Orsulic S, Kemler R (2000) Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. J Cell Sci 113: 1793–1802. |
[9] | Janis LS, Cassidy RM, Kromer LF (1999) Ephrin-A binding and EphA receptor expression delineate the matrix compartment of the striatum. J Neurosci 19: 4962–4971. doi: 10.1523/JNEUROSCI.19-12-04962.1999 |
[10] | Easty DJ, Hill SP, Hsu MY, et al. (1999) Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 84: 494–501. doi: 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.0.CO;2-O |
[11] | Nakamura R, Kataoka H, Sato N, et al. (2005) EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci 96: 42–47. doi: 10.1111/j.1349-7006.2005.00007.x |
[12] | Wykosky J, Debinski W (2008) The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 6: 1795–1806. doi: 10.1158/1541-7786.MCR-08-0244 |
[13] | Yeddula N, Xia Y, Ke E, et al. (2015) Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma. Proc Natl Acad Sci USA 112: E6476–E6485. doi: 10.1073/pnas.1520110112 |
[14] | Alonso-Martin S, Rochat A, Mademtzoglou D, et al. (2016) Gene expression profiling of muscle stem cells identifies novel regulators of postnatal myogenesis. Front Cell Dev Biol 4: 58. |
[15] | Tanabe S, Sato Y, Suzuki T, et al. (2008) Gene expression profiling of human mesenchymal stem cells for identification of novel markers in early- and late-stage cell culture. J Biochem 144: 399–408. doi: 10.1093/jb/mvn082 |
[16] | Tanabe S, Aoyagi K, Yokozaki H, et al. (2014) Gene expression signatures for identifying diffuse-type gastric cancer associated with epithelial-mesenchymal transition. Int J Oncol 44: 1955–1970. doi: 10.3892/ijo.2014.2387 |
[17] | Tanabe S, Kawabata T, Aoyagi K, et al. (2016) Gene expression and pathway analysis of CTNNB1 in cancer and stem cells. World J Stem Cells 8: 384–395. doi: 10.4252/wjsc.v8.i11.384 |
[18] | Gao J, Aksoy BA, Dogrusoz U, et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: pl1. |
[19] | Cerami E, Gao J, Dogrusoz U, et al. (2012) The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401–404. doi: 10.1158/2159-8290.CD-12-0095 |
[20] | Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513: 202–209. doi: 10.1038/nature13480 |
[21] | Uhlén M, Fagerberg L, Hallström BM, et al. (2015) Proteomics. Tissue-based map of the human proteome. Science 347: 1260419. |
[22] | Stelzl U, Worm U, Lalowski M, et al. (2005) A human protein-protein interaction network: a resource for annotating the proteome. Cell 122: 957–968. doi: 10.1016/j.cell.2005.08.029 |
[23] | Janis LS, Cassidy RM, Kromer LF (1999) Ephrin-A binding and EphA receptor expression delineate the matrix compartment of the striatum. J Neurosci 19: 4962–4971. doi: 10.1523/JNEUROSCI.19-12-04962.1999 |
[24] | Lackmann M, Mann RJ, Kravets L, et al. (1997) Ligand for EPH-related kinase (LERK) 7 is the preferred high affinity ligand for the HEK receptor. J Biol Chem 272: 16521–16530. doi: 10.1074/jbc.272.26.16521 |
[25] | Vinayagam A, Stelzl U, Foulle R, et al. (2011) A directed protein interaction network for investing intracellular signal transduction. Sci Signal 4: rs8. doi: 10.1126/scisignal.2001446 |
[26] | McKinney N, Yuan L, Zhang H, et al. (2015) EphrinB1 expression is dysregulated and promotes oncogenic signaling in medulloblastoma. J Neurooncol 121: 109–118. doi: 10.1007/s11060-014-1618-8 |
[27] | Zantek ND, Azimi M, Fedor-Chaiken M, et al. (1999) E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 10: 629–638. |
[28] | Lee JH, Kim Y, Choi JW, et al. (2015) Genetic variants and risk of gastric cancer: a pathway analysis of a genome-wide association study. SpringerPlus 4: 215. doi: 10.1186/s40064-015-1005-8 |
[29] | Zhang K, Chang S, Cui S, et al. (2011) ICSNPathway: identify candidate causal SNPs and pathways from genome-wide association study by one analytical framework. Nucleic Acids Res 39: W437–443. doi: 10.1093/nar/gkr391 |
[30] | Zhu H, Yang M, Zhang H, et al. (2015) Genome-wide association pathway analysis to identify candidate single nucleotide polymorphisms and molecular pathways for gastric adenocarcinoma. Tumour Biol 36: 5635–5639. doi: 10.1007/s13277-015-3236-2 |
[31] | Yuan WJ, Ge J, Chen ZK, et al. (2009) Over-expression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Dig Dis Sci 54: 2410–2417. doi: 10.1007/s10620-008-0649-4 |
[32] | Katoh Y, Katoh M (2006) Comparative integromics on Ephrin family. Oncol Rep 15: 1391–1395. |
[33] | Chen J, Song W, Amato K. (2015) Eph receptor tyrosine kinases in cancer stem cells. Cytokine Growth Factor Rev 26: 1–6. doi: 10.1016/j.cytogfr.2014.05.001 |
[34] | Batlle E, Henderson JT, Beghtel H, et al. (2002) Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111: 251–263. doi: 10.1016/S0092-8674(02)01015-2 |
[35] | De Robertis M, Loiacono L, Fusilli C, et al. (2017) Dysregulation of EGFR pathway in EphA2 cell subpopulation significantly associates with poor prognosis in colorectal cancer. Clin Cancer Res 23: 159–170. doi: 10.1158/1078-0432.CCR-16-0709 |
[36] | Alonso-Martin S, Rochat A, Mademtzoglou D, et al. (2016) Gene expression profiling of muscle stem cells identifies novel regulators of postnatal myogenesis. Front Cell Dev Biol 4: 58. |
[37] | Miao H, Gale NW, Guo H, et al. (2015) EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties. Oncogene 34: 558–567. doi: 10.1038/onc.2013.590 |
[38] | Hao PP, Lee MJ, Yu GR, et al. (2013) Isolation of EpCAM+/CD133− hepatic progenitor cells. Mol Cells 36: 424–431. doi: 10.1007/s10059-013-0190-y |